lenalidomide has been researched along with Granulocytic Leukemia in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bacher, U; Braulke, F; Brümmendorf, TH; Bug, G; Büsche, G; Ganser, A; Germing, U; Giagounidis, A; Götze, K; Haas, R; Haase, D; Hofmann, WK; Letsch, A; Lübbert, M; Nolte, F; Platzbecker, U; Schafhausen, P; Schanz, J; Schlenk, RF; Schuler, E; Schulz, X; Shirneshan, K; Trümper, L | 1 |
| Basile, FG | 1 |
| Stone, RM | 1 |
| Aicher, B; Blau, IW; Busse, A; Dabrowski, R; Lohneis, P; Schmidt-Hieber, M; Thiel, E; Weimann, A | 1 |
| Alimena, G; Barzotti, R; Breccia, M; Cannella, L; Ferretti, A; Latagliata, R; Loglisci, G; Nanni, M; Oliva, EN; Santopietro, M | 1 |
| Landgren, O; Mailankody, S; Thomas, A | 1 |
| Abdel-Wahab, O; Berube, C; Coutre, S; Gallegos, L; Gotlib, JR; Greenberg, P; Levine, R; Liedtke, M; Medeiros, BC; Mitchell, BS; Pollyea, DA; Zehnder, J; Zhang, B | 1 |
| Li, CY; Mesa, RA; Steensma, DP; Tefferi, A | 1 |
| Lancet, JE; List, AF; Moscinski, LC | 1 |
1 review(s) available for lenalidomide and Granulocytic Leukemia
| Article | Year |
|---|---|
How I treat patients with myelodysplastic syndromes.
Topics: Acute Disease; Aged; Azacitidine; Chelation Therapy; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Decitabine; Disease Progression; DNA Methylation; Erythropoietin; Hematopoietic Cell Growth Factors; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Lenalidomide; Leukemia, Myeloid; Myelodysplastic Syndromes; Severity of Illness Index; Thalidomide; Transplantation, Homologous | 2009 |
2 trial(s) available for lenalidomide and Granulocytic Leukemia
| Article | Year |
|---|---|
Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antigens, CD34; Chromosome Banding; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease-Free Survival; Female; Germany; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Lenalidomide; Leukemia, Myeloid; Leukocytes, Mononuclear; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Thalidomide; Treatment Failure | 2017 |
Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; fms-Like Tyrosine Kinase 3; Humans; Kaplan-Meier Estimate; Lenalidomide; Leukemia, Myeloid; Male; Middle Aged; Mutation; Nausea; Nuclear Proteins; Nucleophosmin; Prognosis; Remission Induction; Thalidomide; Treatment Outcome; Vomiting | 2013 |
6 other study(ies) available for lenalidomide and Granulocytic Leukemia
| Article | Year |
|---|---|
Durable clinical and cytogenetic remission in an elderly patient with relapsed acute myeloid leukemia treated with low-dose lenalidomide.
Topics: Acute Disease; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Pair 5; Decitabine; Humans; Lenalidomide; Leukemia, Myeloid; Male; Neoplasm Recurrence, Local; Remission Induction; Thalidomide | 2009 |
In vitro cytotoxicity of the novel antimyeloma agents perifosine, bortezomib and lenalidomide against different cell lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Flow Cytometry; HL-60 Cells; Humans; Immunohistochemistry; Inhibitory Concentration 50; K562 Cells; Ki-67 Antigen; Lenalidomide; Leukemia, Myeloid; Lymphoma; Multiple Myeloma; Phosphorylcholine; Pyrazines; Thalidomide; Time Factors | 2012 |
Sudden acute leukemia transformation in a MDS patient with del(5q) in complete cytogenetic remission after lenalidomide.
Topics: Acute Disease; Aged; Antineoplastic Agents; Cell Transformation, Neoplastic; Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Lenalidomide; Leukemia, Myeloid; Male; Myelodysplastic Syndromes; Spectral Karyotyping; Thalidomide | 2011 |
Myeloma and second primary cancers.
Topics: Antineoplastic Agents; Humans; Lenalidomide; Leukemia, Myeloid; Melphalan; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms, Second Primary; Probability; Risk Assessment; Thalidomide | 2011 |
Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2(V617F) positive, del(5)(q13q33) myelodysplastic syndrome.
Topics: Acute Disease; Aged, 80 and over; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Janus Kinase 2; Lenalidomide; Leukemia, Myeloid; Myelodysplastic Syndromes; Point Mutation; Thalidomide | 2006 |
Treatment of deletion 5q acute myeloid leukemia with lenalidomide.
Topics: Acute Disease; Antineoplastic Agents; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide; Leukemia, Myeloid; Middle Aged; Primary Myelofibrosis; Remission Induction; Thalidomide | 2007 |